Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy
about
Chemotherapy-induced peripheral neurotoxicity: a critical analysisGenetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancerPathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients.Predicting acute and persistent neuropathy associated with oxaliplatin.Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studiesOxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer.Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.Alpha-class glutathione S-transferases in wild turkeys (Meleagris gallopavo): characterization and role in resistance to the carcinogenic mycotoxin aflatoxin B1Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis.Platinum-induced neurotoxicity and preventive strategies: past, present, and futurePolymorphisms of GSTT1, GSTM1, and EPHX genotypes in patients with cryptogenic polyneuropathy: a case-control study.Informative gene network for chemotherapy-induced peripheral neuropathyMultiplex PCR detection of GSTM1, GSTT1, and GSTP1 gene variants: simultaneously detecting GSTM1 and GSTT1 gene copy number and the allelic status of the GSTP1 Ile105Val genetic variant.Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.Glutathione s-transferase p1: gene sequence variation and functional genomic studies.Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs.Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.Can GSTM1 and GSTT1 polymorphisms predict clinical outcomes of chemotherapy in gastric and colorectal cancers? A result based on the previous reports.Platinum neurotoxicity pharmacogeneticsMice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuliCumulative genetic risk predicts platinum/taxane-induced neurotoxicity.Pharmacogenetics in colorectal cancer: a systematic review.Neurological Adverse Effects in Patients of Advanced Colorectal Carcinoma Treated with Different Schedules of FOLFOXPharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathyGlutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma.A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Neurocognitive functioning and genetic variation in patients with primary brain tumours.Macular Pigment Optical Density and Measures of Macular Function: Test-Retest Variability, Cross-Sectional Correlations, and Findings from the Zeaxanthin Pilot Study of Response to Supplementation (ZEASTRESS-Pilot).Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications.Biomarker-based selection of therapy for colorectal cancer.Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.
P2860
Q27010318-F692E19E-9350-4C51-A62A-5F5B1FD31142Q33386412-8E6C56E6-4B78-4AFE-8A6F-1F906470BF48Q33391561-5E841EC4-D080-48EF-8944-48BAF87A7263Q33422082-2D5A6CAC-C3F5-4C6D-B0CF-36C11174C295Q33744706-45A7389F-731A-4857-B2E4-5B3BA7D6D9E4Q33816134-75B4FE55-77D9-4894-8579-8A60B0AFA356Q33841734-F0428721-38CA-4555-9E3C-9200FD025839Q33879736-32307F50-AB1B-4E8F-B119-5CE5799CF27EQ34023788-48355907-0883-421E-AB3C-FA0AEB2B3B8EQ34494728-9353DFAA-F316-471C-92A1-408D16B5E2D6Q34627846-5224B013-A834-42A4-8A0D-6B66F4D0CFE8Q34682560-859C1CC6-40F8-4A6E-986B-2B39A0578714Q34683728-2D4B3AC0-289F-4ED5-A296-EA4E8B5CC801Q34733071-55384811-273F-428C-823D-60592A69153BQ35345734-E9A0EC10-D015-4BB9-BC9B-E7288779A449Q35609321-C81192DB-BEE6-4C59-90BB-E27559DE7F6FQ35945680-167A622D-C5F8-4630-83B2-3EC5CC4B4C06Q36103456-819C7385-B5B2-4A13-B56B-7424CA6E248FQ36219923-39CEE2E0-68F7-4AB4-994C-D5F9CE8B3A20Q36412220-BDB21D5E-AE94-422F-A247-D746C89FD865Q36530731-31E0CEC4-F9F7-44A8-90A0-B8DC88EF967FQ36636872-6DD75BC1-1BF0-471D-91BE-B900FEF42C33Q36798838-03C5A0AC-9488-439F-BB7D-71A13A0018A7Q36847276-624743D6-8835-4283-8743-4E5581B09DD7Q36936011-FF004C90-C131-4FFC-B6D0-BC557FC223DEQ37042575-D1233DE0-A004-4AC7-BA9C-854460A8A655Q37118862-F75EF651-2D57-486A-A240-C15C8876A79CQ37127360-376B282E-A90E-49FD-A5AE-3DD16F753D62Q37233810-77E2F926-89A1-4AB8-B2A8-D59DEDC53A9AQ37235638-647BA7A8-361F-4E4C-B97B-1FBB170C8568Q37244795-29A00BFC-63BC-4663-B62C-7E724705D3BFQ37251569-6A9CAE15-BA0F-48AA-8791-32AAB4FCB159Q37284259-F956B396-70D5-430F-A12F-7FE1EA6C21ACQ37383249-C7431480-A84F-4241-98D9-BCBAF2BB0F37Q37561807-54466B43-AC2D-4C7B-A7BC-D21C448D3BAAQ37636009-A04AB274-96E7-41F4-8D0B-5AD54F52F91AQ37744263-527D53BF-93F3-47DF-9464-6C8FE3A25635Q37866805-BB47400B-5006-4F48-B873-9AF19BDEA669Q37886995-9A5374EC-4C7A-4110-B2B5-2C9A58B16922Q37887337-3C3D5412-B171-4A35-87B0-1EEF6C2D3B7F
P2860
Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy
description
im Mai 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2006
@uk
name
Glutathione S-Transferase P1 P ...... Oxaliplatin-Based Chemotherapy
@en
Glutathione S-Transferase P1 Polymorphism
@nl
type
label
Glutathione S-Transferase P1 P ...... Oxaliplatin-Based Chemotherapy
@en
Glutathione S-Transferase P1 Polymorphism
@nl
prefLabel
Glutathione S-Transferase P1 P ...... Oxaliplatin-Based Chemotherapy
@en
Glutathione S-Transferase P1 Polymorphism
@nl
P50
P1476
Glutathione S-transferase P1 p ...... oxaliplatin-based chemotherapy
@en
P2093
Bruno Landi
Thierry Lecomte
P304
P356
10.1158/1078-0432.CCR-05-2076
P407
P577
2006-05-01T00:00:00Z